The Effects of 12-months of Denosumab on Bone Density, Quality, and Strength in Prevalent Kidney Transplant Recipients
Study of Prolia (Denosumab) in Subjects with Kidney Transplants
Sponsor: Amgen
Enrolling: Male and Female Patients
Study Length: 1 Years
Clinic Visits: 7
IRB Number: AAAS3103
U.S. Govt. ID: NCT03960554
Contact: Maria A. Aponte Farias: 212-305-3273 / maa2308@cumc.columbia.edu
Additional Study Information: Kidney transplant patients are at a higher risk for bone fractures compared to the general population. We are doing a clinical trial to examine the effects of 12-months of treatment with denosumab, a monoclonal antibody against RANKL, on bone density and strength as determined by bone imaging and by non-invasive measures of bone activity from blood and questionnaires.
This study is closed
Investigator
Thomas Nickolas, MD, MS
Do You Qualify?
Have you had a stable kidney transplant that occurred over 1 year ago? Yes No
Do you have a history of cancer? Yes No
Have you had a parathyroidectomy within the past year? Yes No
Are you pregnant or planning on getting pregnant over the course of the study? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Maria A. Aponte Farias
maa2308@cumc.columbia.edu
212-305-3273
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE